Kronox Lab Sciences Ltd(KRONOX)

NSE: KRONOXBSE: 544187

₹ 186.7-2.35%refreshed 26 Oct, 03:57 pm ISTMarket cap: ₹ 693 crWebsite: www.kronoxlabsciences.comUpdated: 27 Oct 2026

About

Kronox Lab Sciences makes High Purity Speciality Fine Chemicals and has a portfolio of about 185 products, including excipients, high purity reagents, and pharmaceutical, nutraceutical and food chemicals. Its chairman calls it a leading manufacturer in this field, a position built over 1.5 decades. It runs three manufacturing units in Padra, Vadodara, with installed capacity of 7,242 MTPA as of FY25. Revenue in FY26 was 101.22 crore.^[1][2]

Business segment

The company reports one segment, chemicals manufacturing. Sale of products was 10,019.39 lakh in FY25, up from 8,986.24 lakh in FY24.^[1]

Products

As of FY25, the portfolio of High Purity Speciality Fine Chemicals has about 185 products.^[1]
As of FY25, the range covers excipients and ingredients, high purity reagents, and pharmaceutical, nutraceutical and food chemicals.^[1]
As of FY25, its products serve pharma, nutraceuticals, biotech, agrochem, personal care, metallurgy and animal health.^[1]
The FY25 annual report says the company built its portfolio with a steady focus on backward and forward integration.^[1]

Manufacturing and certifications

As of FY25, installed capacity is 7,242 MTPA across 3 manufacturing facilities.^[1]
As of FY25, the three units lie within a 1 km radius in Ekalbara village, Padra, Vadodara district, with air, water and road connectivity.^[1][3]
In 2025 the company began manufacturing at Unit II and got FSSAI certification for making food grade fine chemicals.^[1]
As of FY25, Unit I and Unit II hold ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 certifications.^[1]
As of FY25, Unit I holds FSSC 22000, GMP, GLP, Kosher and Halal certifications.^[1]

Customers and exports

Exports were 26.57% of revenue in FY25, compared with 24.75% in FY24.^[1]
Foreign exchange earnings were 2639.85 lakh in FY25, up from 2168.01 lakh in FY24.^[1]
As of FY25, the company has long-term supply commitments with customers in India and abroad.^[1]
The company's list of milestones shows that it began exporting High Purity Specialty Fine Chemicals early in its history.^[1]

Expansion

Unit IV is planned on a 20,471 sq m leasehold plot at GIDC Dahej-II, acquired in FY24, to add capacity.^[3][1]
As of FY25, local and state permissions for Dahej are in place. Construction will start once the Central Government grants environmental clearance, which is pending.^[1]
The company plans to add more high purity speciality fine chemicals at Dahej, such as acetate, adipate, ascorbate, citrate and glycinate derivatives.^[1][3]

Market position and risks

In the FY25 report, the chairman describes Kronox as a leading manufacturer of High Purity Speciality Fine chemicals, built over 1.5 decades.^[1]
The FY25 report names two entry barriers: the large investment needed for facilities, and the time needed to build technical skill, R&D, new product development and testing capability.^[1]
The FY25 report sees India benefiting as buyers, including chemical buyers, diversify their supply away from China.^[1]
The FY25 report names Middle East conflicts, disruption to trade routes and foreign exchange volatility as risks.^[1]

Listing

The shares listed on NSE and BSE on 10 June 2024. The IPO was a 100% offer for sale of 95,70,000 shares at ₹136, so the company received no proceeds.^[3]

Market Cap

₹693 Cr

High / Low

₹227 / 96

Stock P/E

25.2

Price / Book

6.2

Book Value

₹31

EPS

₹7.5

No. of Shares

3.71 Cr

ROCE

36.0%

ROE

26.8%

OPM

35.2%

Debt / Equity

0.01

Sales

₹101 Cr

Net Profit

₹28 Cr

Promoter holding

64.3%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

No earnings calls are on record for this company, so our models read its annual report and financials end-to-end - then value the business and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
P&L bridge from reported history - worst / average / best multiple cases.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials